Updates are available Correction dated 2018-08-09
Click to view Correction: https://doi.org/10.1007/s00401-018-1887-y
-
Authors
Capper, David
Engel, Nils W.
Stichel, Damian
Lechner, Matt
Glöss, Stefanie
Schmid, Simone
Koelsche, Christian
Schrimpf, Daniel
Niesen, Judith
Wefers, Annika K.
Jones, David T. W.
Sill, Martin
Weigert, Oliver
Ligon, Keith L.
Olar, Adriana
Koch, Arend
Forster, Martin
Moran, Sebastian
Tirado, Oscar M.
Sáinz-Jaspeado, Miguel
Mora, Jaume
Esteller, Manel
Alonso, Javier
del Muro, Xavier Garcia
Paulus, Werner
Felsberg, Jörg
Reifenberger, Guido
Glatzel, Markus
Frank, Stephan
Monoranu, Camelia M.
Lund, Valerie J.
von Deimling, Andreas
Pfister, Stefan
Buslei, Rolf
Ribbat-Idel, Julika
Perner, Sven
Gudziol, Volker
Meinhardt, Matthias
Schüller, Ulrich http://orcid.org/0000-0002-8731-1121
-
Funding
Funding for this research was provided by:
Fördergemeinschaft Kinderkrebs-Zentrum Hamburg
Deutsche Krebshilfe (111630)
- License Information
-
More Information
Article History
Received: 11 October 2017
Revised: 15 March 2018
Accepted: 26 April 2018
First Online: 5 May 2018
Change Date: 9 August 2018
Change Type: Correction
Change Details: In the original publication, the second name of the twentieth author was incorrect. It should read as ‘Miguel Sáinz-Jaspeado’. The original publication of the article has been updated to reflect the change. This correction was authored by Ulrich Schüller on behalf of all authors of the original publication.
Compliance with ethical standards
:
: Andreas von Deimling, David Jones, and David Capper share inventorship of a “DNA-methylation-based method for classifying tumor species of the brain”. A patent has been applied for this method (EP 3067432 A1). All terms are being managed by the German Cancer Research Center in accordance with its conflict of interest policies. G. Reifenberger has received research grants from Roche and Merck Serono, and honoraria for lectures or advisory boards from Amgen and Celldex. The other authors declare no conflicts of interest.
